Adaptive Biotechnologies sees stock surge after clonoSEQ EU certification

Pallavi Madhiraju- September 26, 2024 0

In a major development for the biotechnology sector, Adaptive Biotechnologies Corporation witnessed a remarkable 29% surge in its stock value following a key regulatory milestone. ... Read More

Bristol Myers Squibb CAR T cell therapy Breyanzi shows promising outcomes in clinical trials

Pallavi Madhiraju- December 11, 2023 0

Bristol Myers Squibb (NYSE: BMY) has unveiled primary analysis results from the TRANSCEND FL clinical trial at the 2023 American Society of Hematology (ASH) Annual ... Read More

FDA accepts review of Dr. Reddy’s biosimilar rituximab candidate, DRL_RI

Pallavi Madhiraju- July 12, 2023 0

Dr. Reddy's Laboratories, an Indian pharmaceutical company, announced that the US Food and Drug Administration (FDA) has accepted its Biologics License Application (BLA) for a ... Read More

Lilly announces promising results for Pirtobrutinib Phase 1/2 trials

Pallavi Madhiraju- July 7, 2023 0

Eli Lilly's oncology arm, Loxo@Lilly, disclosed that The New England Journal of Medicine (NEJM) has published an extensive analysis of results from the BRUIN Phase ... Read More

BeiGene gets Brukinsa FDA approval for chronic lymphocytic leukemia

Raghuram Kadari- January 21, 2023 0

BeiGene has secured the approval of the US Food and Drug Administration (FDA) for the company’s Brukinsa (zanubrutinib) for the treatment of adult patients with ... Read More

AbbVie’s ibrutinib, venetoclax combo succeeds in phase 3 GLOW study

pallavi123- June 13, 2021 0

AbbVie said that the phase 3 GLOW study in chronic lymphocytic leukemia (CLL) investigating the combination of IMBRUVICA (ibrutinib) plus VENCLEXTA/VENCLYXTO (venetoclax) (I+V) has met ... Read More

Ascentage, Acerta to evaluate APG-2575, CALQUENCE combo in r/r CLL/SLL

pharmanewsdaily- June 22, 2020 0

Ascentage Pharma has entered into a clinical collaboration with Acerta Pharma, the hematology research and development center of excellence of AstraZeneca to assess the combination ... Read More